CASIA OpenIR  > 中国科学院分子影像重点实验室
Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk
He, Bing-Xi1,2,3; Zhong, Yi-Fan4; Zhu, Yong-Bei1,2,3; Deng, Jia-Jun4; Fang, Meng-Jie3; She, Yun-Lang4; Wang, Ting-Ting5; Yang, Yang5; Sun, Xi-Wen5; Belluomini, Lorenzo6,7; Watanabe, Satoshi8; Dong, Di3,9; Tian, Jie1,2,3; Xie, Dong4
发表期刊TRANSLATIONAL LUNG CANCER RESEARCH
ISSN2218-6751
2022-04-15
页码23
摘要

Background: Radiomics based on computed tomography (CT) images is potential in promoting individualized treatment of non-small cell lung cancer (NSCLC), however, its role in immunotherapy needs further exploration. The aim of this study was to develop a CT-based radiomics score to predict the efficacy of immune checkpoint inhibitor (ICI) monotherapy in patients with advanced NSCLC. Methods: Two hundred and thirty-six ICI-treated patients were retrospectively included and divided into a training cohort (n=188) and testing cohort (n=48) at a ratio of 8 to 2. The efficacy outcomes of ICI were evaluated based on overall survival (OS) and progression-free survival (PFS). We designed a survival network and combined it with a Cox regression model to obtain patients' OS risk score (OSRS) and PFS risk score (PFSRS). Results: Based on OSRS and PFSRS, patients were divided into high-and low-risk groups in the training cohort and the test cohort with distinctly different [training cohort, log-rank P<0.001, hazard ratio (HR): 4.14; test cohort, log-rank P=0.014, HR: 4.54] and PFS (training cohort, log-rank P<0.001, HR: 4.52; test cohort, log-rank P<0.001, HR: 6.64). Further joint evaluation of OSRS and PFSRS showed that both were significant in the Cox regression model (P<0.001), and multi-overall survival risk score (MOSRS) displayed more outstanding stratification capabilities than OSRS in both the training (P<0.001) and test cohorts (P=0.002). None of the clinical characteristics were significant in the Cox regression model, and the score that predicted the best immune response was not as good as the risk score from follow-up information in the performance of prognostic stratification. Conclusions: We developed a CT imaging-based score with the potential to become an independent prognostic factor to screen patients who would benefit from ICI treatment, which suggested that CT radiomics could be applied for individualized immunotherapy of NSCLC. Our findings should be further validated by future larger multicenter study.

关键词Tumor biomarkers immunotherapy lung neoplasms programmed cell death 1 receptor (PD-1 receptor) biostatistics
DOI10.21037/tlcr-22-244
关键词[WOS]GASTRIC-CANCER ; RADIOMICS ; BLOCKADE ; DOCETAXEL ; NIVOLUMAB ; ANTIBODY ; PD-1
收录类别SCI
语种英语
资助项目National Key R&D Program of China[2017YFA0205200] ; National Natural Science Foundation of China[91959126] ; National Natural Science Foundation of China[82022036] ; National Natural Science Foundation of China[91959130] ; National Natural Science Foundation of China[81971776] ; National Natural Science Foundation of China[81771924] ; National Natural Science Foundation of China[6202790004] ; National Natural Science Foundation of China[81930053] ; National Natural Science Foundation of China[9195910169] ; Beijing Natural Science Foundation[L182061] ; Strategic Priority Research Program of Chinese Academy of Sciences[XDB38040200] ; Chinese Academy of Sciences[GJJSTD20170004] ; Chinese Academy of Sciences[QYZDJ-SSW-JSC005] ; Shanghai Municipal Health Commission[2018ZHYL0102] ; Tongji University AI Program[22120190216] ; Youth Innovation Promotion Association CAS[2017175] ; China Postdoctoral Science Foundation[2021M700341]
项目资助者National Key R&D Program of China ; National Natural Science Foundation of China ; Beijing Natural Science Foundation ; Strategic Priority Research Program of Chinese Academy of Sciences ; Chinese Academy of Sciences ; Shanghai Municipal Health Commission ; Tongji University AI Program ; Youth Innovation Promotion Association CAS ; China Postdoctoral Science Foundation
WOS研究方向Oncology ; Respiratory System
WOS类目Oncology ; Respiratory System
WOS记录号WOS:000790593000001
出版者AME PUBL CO
七大方向——子方向分类医学影像处理与分析
引用统计
被引频次:13[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.ia.ac.cn/handle/173211/48417
专题中国科学院分子影像重点实验室
通讯作者Dong, Di; Tian, Jie; Xie, Dong
作者单位1.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Sch Engn Med, Beijing, Peoples R China
2.Beihang Univ, Key Lab Big Data Based Precis Med, Minist Ind & Informat Technol, Beijing, Peoples R China
3.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Beijing, Peoples R China
4.Tongji Univ, Dept Thorac Surg, Shanghai Pulm Hosp, Sch Med, Shanghai, Peoples R China
5.Tongji Univ, Shanghai Pulm Hosp, Dept Radiol, Sch Med, Shanghai, Peoples R China
6.Univ Verona, Dept Med, Sect Oncol, Sch Med, Verona, Italy
7.Verona Univ Hosp Trust, Verona, Italy
8.Niigata Univ, Dept Resp Med & Infect Dis, Grad Sch Med & Dent Sci, Niigata, Japan
9.Univ Chinese Acad Sci, Sch Artificial Intelligence, Beijing, Peoples R China
第一作者单位中国科学院自动化研究所
通讯作者单位中国科学院自动化研究所
推荐引用方式
GB/T 7714
He, Bing-Xi,Zhong, Yi-Fan,Zhu, Yong-Bei,et al. Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk[J]. TRANSLATIONAL LUNG CANCER RESEARCH,2022:23.
APA He, Bing-Xi.,Zhong, Yi-Fan.,Zhu, Yong-Bei.,Deng, Jia-Jun.,Fang, Meng-Jie.,...&Xie, Dong.(2022).Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk.TRANSLATIONAL LUNG CANCER RESEARCH,23.
MLA He, Bing-Xi,et al."Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk".TRANSLATIONAL LUNG CANCER RESEARCH (2022):23.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Deep learning for pr(3742KB)期刊论文出版稿开放获取CC BY-NC-SA浏览
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[He, Bing-Xi]的文章
[Zhong, Yi-Fan]的文章
[Zhu, Yong-Bei]的文章
百度学术
百度学术中相似的文章
[He, Bing-Xi]的文章
[Zhong, Yi-Fan]的文章
[Zhu, Yong-Bei]的文章
必应学术
必应学术中相似的文章
[He, Bing-Xi]的文章
[Zhong, Yi-Fan]的文章
[Zhu, Yong-Bei]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients a retrospective study combining progression-free survival risk and overa.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。